Beranda › Limfoma › Missouri › St. Louis
Uji klinis Limfoma di St. Louis, MO
15 studi untuk Limfoma mencari peserta di lokasi sekitar St. Louis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Menerima pesertaFase 1
- Washington University School of Medicine - Oncology Hospital - Public, St Louis
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Menerima pesertaFase 2
- Washington University School of Medicine in St. Louis, St Louis
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Menerima pesertaFase 1/2
- Washington University School of Medicine in St. Louis, St Louis
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Menerima pesertaFase 1
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at West County Hospital, Creve Coeur · 12 mi jauhnya
Collection of Tissue Samples for Cancer Research
Menerima pesertaStudi observasional
- Washington University - St. Louis, St Louis
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Menerima pesertaFase 1/2
- Washington University School of Medicine, St Louis
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Menerima pesertaFase 1
- Washington University School of Medicine, St Louis
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Menerima pesertaFase 1
- Washington University School of Medicine/Siteman Cancer Center, St Louis
DALY II USA/ MB-CART2019.1 for DLBCL
Menerima pesertaFase 2
- Washington University, St. Louis, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Menerima peserta
- Washington University School of Medicine, St Louis
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Menerima pesertaStudi observasional
- Washington University School of Medicine, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Menerima pesertaFase 3
- Saint Louis University, St Louis
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Menerima pesertaFase 2
- Washington University, St Louis
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
Menerima pesertaFase 3Sukarelawan sehat diterima
- OSF Saint Anthony's Health Center, Alton · 18 mi jauhnya
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Menerima pesertaFase 1/2
- Washington University, St Louis
Uji klinis Limfoma di kota lain
- Houston, TX34 studi
- Boston, MA33 studi
- New York City, NY33 studi
- Washington, DC23 studi
- Baldwin Park, CA21 studi
- Chicago, IL20 studi
- Durham, NC17 studi
- Philadelphia, PA15 studi
- Cleveland, OH14 studi
- Edison, NJ12 studi
- Atlanta, GA12 studi
- Seattle, WA12 studi
Studi lain di St. Louis
- Kanker Paru Non-Sel Kecil73 studi
- Kanker Payudara64 studi
- Kanker Metastatik54 studi
- Kanker Kolorektal50 studi
- Kanker Prostat46 studi
- Kanker (semua jenis)46 studi
- Kanker Paru39 studi
- Kanker Ovarium38 studi
- Kanker Pankreas33 studi
- Kanker Endometrium29 studi
- Karsinoma Sel Skuamosa Kepala dan Leher28 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.